Brokerages Set X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Price Target at $34.50

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) have been assigned a consensus rating of “Hold” from the five brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $34.50.

A number of brokerages have weighed in on XFOR. Stifel Nicolaus set a $10.00 price objective on X4 Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, December 5th. Wall Street Zen downgraded shares of X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, November 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of X4 Pharmaceuticals in a report on Monday, December 29th. Finally, Zacks Research downgraded X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 26th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Rhumbline Advisers boosted its holdings in X4 Pharmaceuticals by 5.4% in the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after purchasing an additional 9,690 shares in the last quarter. Indivisible Partners purchased a new stake in shares of X4 Pharmaceuticals in the fourth quarter valued at approximately $40,000. Squarepoint Ops LLC purchased a new stake in shares of X4 Pharmaceuticals in the fourth quarter valued at approximately $50,000. Two Sigma Investments LP acquired a new position in X4 Pharmaceuticals during the third quarter worth $47,000. Finally, Palumbo Wealth Management LLC raised its position in X4 Pharmaceuticals by 18.9% in the fourth quarter. Palumbo Wealth Management LLC now owns 113,357 shares of the company’s stock worth $453,000 after acquiring an additional 18,030 shares in the last quarter. 72.03% of the stock is currently owned by institutional investors and hedge funds.

X4 Pharmaceuticals Stock Up 5.8%

XFOR opened at $3.44 on Wednesday. X4 Pharmaceuticals has a one year low of $1.35 and a one year high of $12.55. The company has a debt-to-equity ratio of 1.23, a quick ratio of 5.48 and a current ratio of 5.65. The stock has a market capitalization of $300.79 million, a P/E ratio of -0.34 and a beta of 0.43. The business’s 50-day simple moving average is $3.73 and its 200-day simple moving average is $3.58.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.